Anteris Technologies (ASX: AVR) — Perfil da empresa, notícias e dados financeiros
Anteris Technologies is focused on structural heart solutions, with its DurAVR™ THV valve mimicking human aortic valve performance.
Anteris Technologies
Anteris Technologies is a structural heart company focused on developing novel medical devices for heart valve replacement and repair. The company's lead product candidate is the DurAVR Transcatheter Heart Valve, a biomimetic single-piece aortic valve designed to restore native laminar blood flow patterns in patients suffering from severe aortic stenosis. Anteris utilizes its proprietary ADAPT tissue engineering technology, an advanced anti-calcification process, to improve tissue durability and bio-integration in cardiovascular applications. The company conducts international clinical trials to support global regulatory approvals and advancement of its cardiovascular therapeutic platform.
Resumo
Operações
Produtos e/ou serviços de Anteris Technologies
- Transcatheter Heart Valves: Single-piece native-shaped biomimetic aortic valves engineered to restore healthy physiologic laminar blood flow patterns in adult patients undergoing transcatheter aortic valve replacement for treatment of severe aortic stenosis.
- Tissue Treatment Technology: Proprietary anti-calcification tissue processing platforms designed to optimize bovine pericardium durability, biocompatibility, and hemodynamic performance for structural heart valve implants and general soft tissue surgical reconstruction applications.
- Valve Delivery Systems: Specialized catheter delivery tools developed to facilitate precise anatomical positioning, controlled deployment, and commissural alignment of transcatheter heart valves during minimally invasive cardiovascular surgical procedures across global clinical sites.
- Global Clinical Studies: Multi-center clinical trials evaluating post-procedure aortic blood flow, hemodynamics, safety profiles, and left ventricular mass regression using cardiac MRI across medical centers in North America and Europe.
- Surgical Reconstruction Patches: Processed biological tissue repair products incorporating anti-calcification treatment for cardiovascular reconstruction, vascular repair, dura mater reinforcement, and general soft tissue surgical applications in international medical and hospital environments.
- Cardiac Imaging and Analytics: Specialized diagnostic evaluations utilizing cardiac MRI metrics to quantify post-implantation laminar flow, pressure gradients, effective orifice area, and long-term cardiac remodeling in heart valve replacement cohorts.
equipe executiva do Anteris Technologies
- Wayne Geoffrey PatersonVice Chairman & CEO
- David St. DenisPresident & Director
- Matthew McDonnellHead of Australia
- Brent A. MoenChief Financial Officer
- Chris MeduriChief Medical Officer & Member of Medical Advisory Board
Últimas notícias sobre a Anteris Technologies
Anteris Technologies Global names new CFO
AustraliaAnteris Technologies reports Q2 results and trial updates
AustraliaAnteris Technologies propels heart valve trials with $320M
AustraliaAnteris treats first US patients in PARADIGM trial
AustraliaAnteris clears financial hurdle for pivotal U.S. heart valve trial
AustraliaAnteris Technologies announces $200M public offering
Australia
Comunicados recentes
O que a Anteris Technologies (AVR) comunicou ao mercado, do mais recente para o mais antigo.
- Notification regarding unquoted securities - AVR
- Statement of CDIs on issue - AVR
- Notification of cessation of securities - AVR
- Notification regarding unquoted securities - AVR
- Change of Director's Interest Notice
Principais indicadores financeiros
Resultados divulgados pela Anteris Technologies, em USD.
- Cap. de mercado
- 860,6 mi
- Receita (TTM)
- 2,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,9 mi | -93,9 mi | -94,1 mi | |
| 2,7 mi | -78,4 mi | -76,3 mi | |
| 4,1 mi | -71,4 mi | -67,3 mi | |
| 4,6 mi | -47,4 mi | -44,3 mi |